CliffBio
small molecule

AMINOCAPROIC ACID

AMINOCAPROIC ACID

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMINOCAPROIC ACID
Active ingredientAMINOCAPROIC ACID
Strength0.25GM/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.